This discussion includes both a general overview of non-alcoholic steatohepatitis (NASH) as a disease as well as in-depth discussion of the medications being tested in Phase III trials. To begin, the conversation starts with general commentary surrounding the epidemiology of both NASH and non-alcoholic fatty liver disease (NAFLD), as well as the reliability of the available diagnostic tests for NASH. The conversation then progresses to an in-depth overview of the medications with ongoing Phase III trials in NASH patients. Here, the physician is asked to comment on the available Phase II data of each of these medications, as well as the potential development strategies.

If you are a KOL Insight Subscriber, please access the interview (link) from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.